C.R. Bard, Inc. (NYSE:BCR) Downgraded by BidaskClub to “Sell”

BidaskClub cut shares of C.R. Bard, Inc. (NYSE:BCR) from a hold rating to a sell rating in a report issued on Saturday, August 5th.

BCR has been the subject of several other reports. Zacks Investment Research upgraded shares of C.R. Bard from a hold rating to a buy rating and set a $342.00 price objective for the company in a report on Thursday, May 11th. BMO Capital Markets restated a buy rating and issued a $255.00 price objective on shares of C.R. Bard in a report on Tuesday, April 11th. Raymond James Financial, Inc. lowered shares of C.R. Bard from a strong-buy rating to a mkt perform rating in a research note on Wednesday, April 26th. Wells Fargo & Company downgraded shares of C.R. Bard from an outperform rating to a market perform rating in a research report on Tuesday, April 25th. Finally, Cowen and Company upped their target price on shares of C.R. Bard from $240.00 to $317.00 and gave the stock a market perform rating in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $285.67.

Shares of C.R. Bard (NYSE:BCR) traded down 0.30% during mid-day trading on Friday, reaching $318.20. The company’s stock had a trading volume of 431,723 shares. The firm has a market cap of $23.12 billion, a price-to-earnings ratio of 41.77 and a beta of 0.59. The firm has a 50 day moving average price of $319.58 and a 200 day moving average price of $286.55. C.R. Bard has a 52-week low of $203.63 and a 52-week high of $323.27.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.54 EPS. On average, equities analysts predict that C.R. Bard will post $11.82 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/08/19/bidaskclub-lowers-c-r-bard-inc-nysebcr-to-sell-updated.html.

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. SRS Capital Advisors Inc. increased its stake in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the period. Alps Advisors Inc. increased its stake in shares of C.R. Bard by 0.3% in the second quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after buying an additional 5 shares during the period. KCM Investment Advisors LLC boosted its position in C.R. Bard by 0.5% in the second quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock worth $691,000 after buying an additional 10 shares in the last quarter. Parallel Advisors LLC boosted its position in C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 14 shares in the last quarter. Finally, Creative Planning boosted its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares in the last quarter. Institutional investors own 77.14% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit